● New data to be presented will inform physicians on different aspects of treatment for patients with atrial fibrillation
● Results of RE-DUAL PCI™ trial will be presented in ‘Late Breaking Science in PCI 2’ session on 27 August1
INGELHEIM, Germany-Monday, August 21st 2017 [ AETOS Wire ]
(BUSINESS WIRE) -- Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress.
The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation.
Read more »